Mirus is a recognized leader in developing innovative nucleic acid research reagents, distinguished by its many accomplishments:
- First to develop an siRNA transfection reagent (2001)
- Pioneered development of high efficiency/low toxicity transfection formulation
- First to market a single step nucleic acid labeling technology
Mirus’ TransIT® reagents are unique lipid and polymer formulations that achieve superior delivery efficiency of pDNA and siRNA with minimal cytotoxic effects.
They have been optimized for in vitro delivery in a variety of mammalian cells as well as for in vivo delivery in small animals.